Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients

Cellular Oncology

Volumn 38, Issue 2, 2015, Pages 145-153

  Bichev, Stoyan Naidenov ^a   Marinova, Dora Marinova ^b   Slavova, Yanina Georgieva ^b   Savov, Alexey Slavkov ^a  

^a Obstetrics and Gynaecology Hospital Maichin Dom   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

ARMS PCR; Epidermal growth factor receptor; Mutations; Non small cell lung carcinoma

Indexed keywords

AGED; BULGARIA; CROSS-SECTIONAL STUDY; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTO ONCOGENE;

AGED; BULGARIA; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 84939998737     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0211-7     Document Type: Article

References (36)

1. GLOBOCAN 2008 (IARC) Section of Cancer Information, http://globocan.iarc.fr/. Accessed 21 Sep 2013
2. A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell. Oncol. 36, 265 (2013)
3. P. Boyle, B. Levin, WHO/IARC World Cancer Report 2008 (International Agency for Cancer Research Press, Lyon, 2008)
4. J.R. Molina, P. Yang, S.D. Cassivi, S.E. Schild, A.A. Adjei, Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584 (2008)
5. Y. Miyamae, K. Shimizu, J. Hirato, T. Araki, K. Tanaka, H. Ogawa, S. Kakegawa, M. Sugano, T. Nakano, Y. Mitani, K. Kaira, I. Takeyoshi, Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 25, 921 (2011)
6. N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell. Oncol. 36, 277 (2013)
7. S.H. Ahn, E.H. Jeong, T.G. Lee, S.Y. Kim, H.R. Kim, C.H. Kim, Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells. Cell. Oncol. 37, 377 (2014)
8. W.D. Travis, E. Brambilla, H.K. Muller-Hemerlink, C.C. Harris, World Health Organization classification of tumors. Pathology and genetics of tumours of the lung, pleura, thymus and heart (IARC Press, Lyon, 2004)
9. N. Dimitrova, M. Vukov, Z. Valerianova, Cancer Incidence in Bulgaria 2009 (AVIS-24 Ltd, Sofia, 2011)
10. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl. J. Med. 361, 947 (2009)
11. C. Willmore-Payne, J.A. Holden, C.T. Wittwer, L.J. Layfield, The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non–small cell lung. J. Biomol. Tech. 19, 217 (2008)
12. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350, 2129 (2004)
13. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304, 1497 (2004)
14. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. 101, 13306 (2004)
15. T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, T. Yoshida, T. Tamura, EGFR mutations and gene amplification in NSCLC: molecular analysis of the IDEAL/INTACT Gefitinib trials. J. Clin. Oncol. 23, 6829 (2005)
16. B. Gao, Y. Sun, J. Zhang, Y. Ren, R. Fang, X. Han, L. Shen, X.Y. Liu, W. Pao, H. Chen, H. Ji, Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas. J. Thorac. Oncol. 5, 1130 (2010)
17. A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella, P.P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, F. Buttitta, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23, 857 (2005)
18. R.K. Hsieh, K.H. Lim, H.T. Kuo, C.Y. Tzen, M.J. Huang, Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 128, 317 (2005)
19. A.J. Smits, J.A. Kummer, J.W. Hinrichs, G.J. Herder, K.C. Scheidel-Jacobse, N.M. Jiwa, P.T. Nooijen, M.G. Looijen-Salamon, M.J. Ligtenberg, F.B. Thunnissen, D.A. Heideman, R.A. de Weger, A. Vink, EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell. Oncol. 35, 189 (2012)
20. A.M. Cushman-Vokoun, A.M. Crowley, S.A. Rapp, T.C. Greiner, Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR Pyro assays for mutation analysis in non-small cell lung cancer. Am. J. Clin. Pathol. 140, 7 (2013)
21. N.C. Bae, M.H. Chae, M.H. Lee, K.M. Kim, E.B. Lee, C.H. Kim, T.I. Park, S.B. Han, S. Jheon, T.H. Jung, J.Y. Park, EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet. Cytogenet. 173, 107 (2007)
22. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem, G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J.L. Gonzalez-Larriba, L. Paz-Ares, I. Bover, R. Garcia-Campelo, M.A. Moreno, S. Catot, C. Rolfo, N. Reguart, R. Palmero, J.M. Sánchez, R. Bastus, C. Mayo, J. Bertran-Alamillo, M.A. Molina, J.J. Sanchez, M. Taron, Spanish Lung Cancer Group, Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958 (2009)
23. S. Dearden, J. Stevens, Y.-L. Wu, D. Blowers, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann. Oncol. 24, 2371 (2013)
24. J.L. Marks, M.D. McLellan, M.F. Zakowski, A.E. Lash, Y. Kasai, S. Broderick, I.S. Sarkaria, D. Pham, B. Singh, T.L. Miner, G.A. Fewell, L.L. Fulton, E.R. Mardis, R.K. Wilson, M.G. Kris, V.W. Rusch, H. Varmus, W. Pao, Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One. 2, e426 (2007)
25. G.J. Riely, K.A. Politi, V.A. Miller, W. Pao, Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12, 7232 (2006)
26. H. Cortes-Funes, C. Gomez, R. Rosell, P. Valero, C. Garcia-Giron, A. Velasco, A. Izquierdo, P. Diz, C. Camps, D. Castellanos, V. Alberola, F. Cardenal, J.L. Gonzalez-Larriba, J.M. Vieitez, I. Maeztu, J.J. Sanchez, C. Queralt, C. Mayo, P. Mendez, T. Moran, M. Taron, Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Annals of Oncology. 16, 1081 (2005)
27. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, T. Mitsudomi, Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64, 8919 (2004)
28. Y.H. Soung, J.W. Lee, S.Y. Kim, S.H. Seo, W.S. Park, S.W. Nam, S.Y. Song, J.H. Han, C.K. Park, J.Y. Lee, N.J. Yoo, S.H. Lee, Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 446, 483 (2005)
29. K. Sugio, H. Uramoto, K. Ono, T. Oyama, T. Hanagiri, M. Sugaya, Y. Ichiki, T. So, S. Nakata, M. Morita, K. Yasumoto, Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br. J. Cancer. 94, 896 (2006)
30. Y. Tomizawa, H. Iijima, N. Sunaga, K. Sato, A. Takise, Y. Otani, S. Tanaka, T. Suga, R. Saito, T. Ishizuka, K. Dobashi, J.D. Minna, T. Nakajima, M. Mori, Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 6816 (2005)
31. S.F. Huang, H.P. Liu, L.H. Li, Y.C. Ku, Y.N. Fu, H.Y. Tsai, Y.T. Chen, Y.F. Lin, W.C. Chang, H.P. Kuo, Y.C. Wu, Y.R. Chen, S.F. Tsai, High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195 (2004)
32. G.J. Riely, W. Pao, D. Pham, A.R. Li, N. Rizvi, E.S. Venkatraman, M.F. Zakowski, M.G. Kris, M. Ladanyi, V.A. Miller, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839 (2006)
33. M. Majem, J. Remon, Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl. Lung Cancer Res. 2, 226 (2013)
34. S. Toyooka, K. Kiura, T. Mitsudomi, EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352, 2136 (2005)
35. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Janne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, B. Halmos, EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786 (2005)
36. L. Cheng, R. Alexander, G. MacLennan, O. Cummings, R. Montironi, A. Lopez-Beltran, H. Cramer, D. Davidson, S. Zhang, Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 25, 347 (2012)